Coleman, Jonathan R. I. https://orcid.org/0000-0002-6759-0944
Bryois, Julien https://orcid.org/0000-0002-4747-2166
Gaspar, Héléna A. https://orcid.org/0000-0002-5540-2707
Jansen, Philip R.
Savage, Jeanne E. https://orcid.org/0000-0002-2034-8341
Skene, Nathan
Plomin, Robert
Muñoz-Manchado, Ana B.
Linnarsson, Sten https://orcid.org/0000-0002-3491-3444
Crawford, Greg
Hjerling-Leffler, Jens https://orcid.org/0000-0002-4539-1776
Sullivan, Patrick F.
Posthuma, Danielle https://orcid.org/0000-0001-7582-2365
Breen, Gerome https://orcid.org/0000-0003-2053-1792
Article History
Received: 18 August 2017
Revised: 13 November 2017
Accepted: 2 January 2018
First Online: 8 March 2018
Compliance with ethical standards
:
: PFS reports the following potentially competing financial interests: Lundbeck (advisory committee), Pfizer (Scientific Advisory Board member), and Roche (grant recipient, speaker reimbursement). GB reports consultancy and speaker fees from Eli Lilly and Illumina and grant funding from Eli Lilly. All remaining authors declare that they have no conflict of interest.